miR-29a and miR-222, which are also frequently altered in PD, target anti-inflammatory signaling pathways (e.g., miR-29a targets NLRP3 and miR-222 targets SOCS1), and their dysregulation (downregulation of miR-29a and upregulation of miR-222) enhances NLRP3 inflammasome activity, which exacerbates neuroinflammation. Here, NLRP3 is linked to Parkinson disease.